A perimenopause panel is mostly not hormones. That sounds wrong, and it is the most useful thing to understand before ordering one. Hormone values during the transition move week to week and cycle to cycle, so they establish context rather than settle questions. The markers that change what you actually do — thyroid function, iron stores, insulin sensitivity, ApoB — are stable enough to act on and are left off standard panels at exactly the age they become informative.
The second thing to understand is timing. Half the hormone values on this panel are uninterpretable if drawn on the wrong cycle day, and a progesterone drawn in the first week of a cycle is low in every woman alive. Getting the draw right is not a detail; it is the difference between a result and a number.
The Verdict
The hormone panel — and when to draw each one
Ranges below are common adult reference values. Note that the timing column is not optional guidance; several of these values mean nothing without it.
| Marker | When to draw it | Typical range | How to read it |
|---|---|---|---|
| FSH | Day 2–5 if still cycling; any day if periods have stopped | Under 10 IU/L premenopausal; frequently above 25 IU/L in late transition; above 30–40 postmenopause | Can read menopausal one cycle and premenopausal the next. Useful for confirming postmenopause, close to useless for diagnosing perimenopause |
| Estradiol | Day 2–5 if still cycling | Roughly 30–400 pg/mL across a normal cycle; under 30 pg/mL postmenopause | Swings above premenopausal peaks in some transition cycles. A single normal value excludes nothing |
| Progesterone | Day 19–21 of a 28-day cycle, or 7 days before the expected period | Above 3 ng/mL confirms ovulation occurred | The single most timing-sensitive test on the panel. Drawn on day 5 it is uninformative by definition |
| Total and free testosterone, with SHBG | Any day; morning preferred | Total roughly 15–70 ng/dL in adult women | Declines gradually from the twenties rather than sharply at menopause. Female-range assays matter — many labs run male-calibrated methods that read poorly at low concentrations |
| DHEA-S | Any day; morning preferred | Roughly 35–430 mcg/dL, falling steadily with age | The adrenal precursor pool. Low values sit behind some low-testosterone pictures |
| Prolactin | Any day; avoid after breast stimulation or intense exercise | Under about 25 ng/mL in women | Worth including once. Elevated prolactin causes cycle disruption that can be mistaken for the transition |
The markers that usually change management
These are not obscure or expensive tests. They are ordinary, widely available, and routinely left off the panel at the age they start to matter. The thyroid group is the clearest example: TSH is cheap, on every lab menu, and sits inside the cluster of non-hormonal causes — thyroid disease, iron deficiency, B12 deficiency and sleep disruption — that most often explains symptoms attributed to perimenopause by default.
| Marker group | Target or reference | Why it belongs on a perimenopause panel |
|---|---|---|
| TSH, free T4, free T3, TPO and thyroglobulin antibodies | TSH roughly 0.4–4.0 mIU/L | Thyroid disease is several times more common in women and peaks at the same age as perimenopause. Symptom overlap is nearly total. Antibodies can be positive with a normal TSH for years |
| Ferritin, CBC, transferrin saturation | Ferritin above 30 ng/mL as a minimum; many clinicians prefer 50–100 | Heavy transition bleeding is a common and frequently missed cause of iron deficiency. Fatigue and brain fog appear well before hemoglobin falls |
| Fasting insulin, HbA1c, fasting glucose | Fasting insulin under about 8 uIU/mL; HbA1c under 5.7% | Insulin sensitivity falls across the transition even when weight is stable, and insulin resistance is detectable years before glucose moves |
| ApoB, full lipid panel, Lp(a) once | ApoB under 80 mg/dL for average risk; Lp(a) is measured once in a lifetime | LDL and ApoB rise sharply in the year surrounding the final period, independent of diet. Lp(a) is genetically set and identifies inherited risk that lifestyle will not move |
| hsCRP | Under 1.0 mg/L is low cardiovascular risk; over 3.0 mg/L is high | Interpret only when you are free of acute illness or injury, both of which raise it substantially |
| Vitamin D, B12, magnesium | Vitamin D commonly targeted at 30–50 ng/mL | Correctable deficiencies that mimic or amplify transition symptoms, and vitamin D matters alongside the accelerating bone loss of this window |
| Creatinine, eGFR, liver panel, albumin | Standard reference ranges | Baseline organ function before any medication decision, and albumin is an input to calculated free testosterone |
The cardiovascular group deserves particular weight. Women's LDL cholesterol and ApoB rise sharply in the year surrounding the final menstrual period, independent of diet or weight change. Cardiovascular disease is the leading cause of death in women, and the risk trajectory bends upward at precisely this stage. A one-time Lp(a) — genetically determined, never needing a repeat — identifies inherited risk in roughly one in five people that no lifestyle change will move. Drawing these in late perimenopause gives you a comparison point from before the shift rather than after it.
What invalidates a result
| What goes wrong | Why it matters | What to do instead |
|---|---|---|
| Drawing progesterone on the wrong cycle day | A day-5 progesterone is low in every woman, ovulating or not | Draw 7 days before the expected period; note the actual cycle day on the requisition |
| Hormonal contraception or a hormonal IUD | Combined contraception suppresses FSH and estradiol; the result reflects the drug | Interpret hormones only in that context, or discuss a washout with your clinician. Non-hormone markers stay valid |
| High-dose biotin supplements | Interferes with many immunoassays and can shift thyroid and hormone results in either direction | Stop biotin 48–72 hours before the draw |
| Acute illness, injury or recent surgery | Suppresses thyroid conversion, raises hsCRP, and lowers ferritin interpretability | Wait until recovered |
| Recent iron infusion or a course of oral iron | Ferritin can read falsely reassuring for weeks | Note recent supplementation; recheck later |
| Assuming one draw settles it | FSH and estradiol move week to week in the transition | Repeat hormone values across two or three cycles if they are driving a decision |
| Salivary or dried-urine hormone panels used for dosing | Not validated against serum for guiding hormone therapy decisions | Use serum for anything that will change a prescription |
Reading the panel in combination
Individual values rarely decide anything. Combinations do. The patterns below are the ones that most often change a plan.
| Pattern | What it usually reflects | What to do about it |
|---|---|---|
| Normal FSH and estradiol, classic symptoms, cycle length changing | Early perimenopause with a draw taken in a high-estradiol cycle | Stage clinically from the cycle pattern. Do not let a normal hormone panel close the conversation |
| Fatigue and brain fog with normal hormones | Thyroid disease, iron deficiency, B12 deficiency or sleep disruption | Full thyroid panel with antibodies, ferritin, B12. This combination is the most common non-hormonal explanation |
| Heavy bleeding with low ferritin and a normal hemoglobin | Iron deficiency without anemia | Treat the iron and evaluate the bleeding. Symptoms respond to repletion before hemoglobin ever changes |
| Weight gain around the middle with a normal HbA1c | Early insulin resistance | Fasting insulin and HOMA-IR catch this years before glucose or HbA1c move |
| Rising ApoB with an unchanged LDL | A shift to smaller, more numerous atherogenic particles | ApoB counts particles; LDL cholesterol measures cargo. The particle count is the better risk marker |
| Low testosterone with low DHEA-S | Adrenal precursor decline rather than an ovarian problem | Relevant to libido, energy and lean mass. Testosterone for women is prescribed off-label in the US and needs a clinician |
One combination is worth calling out separately. Fatigue, low mood and cognitive fog with entirely normal hormone values is the most common presentation on this panel, and the most common cause is not hormonal. Iron deficiency without anemia, subclinical or antibody-positive thyroid disease, low B12, obstructive sleep apnea and depression all produce that picture and all have specific treatments. Attributing it to hormones by default delays the diagnosis that would have helped.
What to do with the results
- Treat the correctable findings first. Iron, thyroid, vitamin D and B12 are cheap to fix and account for a large share of the symptoms attributed to the transition.
- Evaluate heavy bleeding rather than supplementing around it. Persistent heavy bleeding needs assessment for fibroids, polyps and endometrial pathology, not just iron.
- Act on ApoB and Lp(a) on their own timeline. These are risk markers, not symptoms, and the intervention window is long. Elevated Lp(a) raises the urgency of controlling everything else that is modifiable.
- Discuss hormone therapy with a clinician who has your history. Systemic therapy has real contraindications — a history of breast cancer, unexplained vaginal bleeding, active liver disease, prior venous thromboembolism or stroke, and known coronary disease among them. Testosterone for women is prescribed off-label in the US and needs monitoring for supraphysiologic levels.
- Retest what trends, not what fluctuates. Annual ApoB, fasting insulin, HbA1c, ferritin and thyroid. Repeat hormones only when a specific decision depends on them.
See a clinician promptly for bleeding after 12 months without a period, bleeding between periods, periods stopping before age 45, a persistently elevated prolactin, or symptoms severe enough to disrupt work and sleep. Each of those is a reason for an appointment rather than another round of testing.
Insulin Resistance In The Menopause Transition
Insulin sensitivity falls during the menopause transition, and the panel above is the natural place to catch it. Falling oestrogen shifts fat storage from the hips and thighs toward the abdomen, including the visceral depot around the organs, and visceral fat raises insulin demand directly. Lean mass declines across the same years, which removes the tissue that disposes of most post-meal glucose.
Neither change announces itself. Body weight can hold steady while both are happening, which is why women frequently describe the same clothes fitting differently at an unchanged number on the scale.
Three markers cover it and none of them is cycle-timed, so they can be drawn on whatever day the hormone panel dictates.
- Fasting insulin. Moves years before glucose does, and has to be requested by name. This is the one that adds information a standard panel does not already have.
- HbA1c. Already on most annual panels, and useful as the slower confirmation rather than as the early signal.
- Triglyceride to HDL ratio. Free if the panel includes lipids, which it should for ApoB anyway.
Waist circumference belongs alongside them and costs nothing. Our pages on fasting insulin and hormone therapy and weight cover how to read the result and what the trials found about hormone therapy's effect on this specific picture.
Frequently Asked Questions
What blood tests should I ask for during perimenopause?
Hormones: FSH, estradiol, progesterone timed to day 19–21, total and free testosterone with SHBG, DHEA-S, and prolactin once. Non-hormones, which are where most decisions actually change: TSH with free T4, free T3 and thyroid antibodies; ferritin with a CBC; fasting insulin and HbA1c; ApoB, a lipid panel and a one-time Lp(a); hsCRP; vitamin D and B12. A standard annual physical covers a fraction of this list.
Can one lab draw diagnose perimenopause?
No. FSH and estradiol fluctuate so widely during the transition that a single draw can read entirely premenopausal in a woman two years from her final period. Perimenopause is staged clinically, from cycle-length change and symptoms in a woman of the right age. The panel is worth running for what else it finds — thyroid disease, iron deficiency, insulin resistance and a rising ApoB all appear at this age and all change what you do.
When exactly should progesterone be drawn?
Seven days before your expected period — day 19 to 21 in a 28-day cycle, later in a longer one. Progesterone rises only after ovulation, so a draw before that point is low regardless of whether you ovulated. A value above 3 ng/mL confirms ovulation occurred in that cycle. This is the single most common timing error on a perimenopause panel, and it makes the result uninterpretable rather than merely imprecise.
Is AMH useful for staging perimenopause?
It reflects ovarian reserve and falls toward undetectable as the final period approaches, so it carries some information about where you are in the arc. It is not recommended as a diagnostic test for the menopausal transition, and it cannot tell you when your final period will be with enough precision to guide a decision. AMH earns its place in fertility assessment rather than in menopause staging.
Are saliva or dried-urine hormone tests worth doing?
Not for anything that will change a prescription. Salivary hormone panels and dried-urine metabolite panels are not validated against serum for guiding hormone therapy dosing, and results correlate poorly with serum concentrations. They are sometimes marketed alongside compounded hormone preparations as a monitoring method. Use serum for any decision involving a dose.
How often should the panel be repeated?
Hormone values every 6 to 12 months add little unless they are driving a specific decision, because they move constantly. The markers worth tracking on a schedule are the ones that trend rather than fluctuate: ApoB, fasting insulin, HbA1c, ferritin and thyroid function, annually or every 6 months if you are actively changing something. Lp(a) is measured once in a lifetime. If you start hormone therapy, expect a symptom review at 6 to 12 weeks and a fuller reassessment at a year.
What does this panel cost?
Ordered through insurance with symptoms documented, much of it is covered — thyroid, CBC, ferritin, lipids, glucose and HbA1c are routine. Self-pay, a broad panel including the hormone and advanced cardiovascular markers typically runs $150 to $400 at direct-to-consumer labs. Physician-led programs that bundle the panel with consults and retesting generally run $150 to $400 a month before any medication.
Related
- Perimenopause symptoms — the symptom picture the panel is ordered to explain
- The 3 stages of menopause — how to stage yourself from cycle pattern
- HRT vs BHRT — what the difference actually is
- ApoB — the marker that shifts fastest across the transition
- Fasting insulin — insulin resistance appears years before glucose moves
- Normal vs optimal ranges — why a reference range is not a target